Metraipolis › archive › dc_ba2a998d3326

Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction? — Europe PMC PMID:42196179

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42196179
DOI
10.3390/ijms27104195
License (as archived)
solo-consultazione
Archived
2026-11-02T13:28:32.121Z
SHA-256 of the archived text
2a2834448e9e7e1a3a99a4b02ec05cff0e2487c11267106e83415f9652e69960
Stable URL of this page
https://metraipolis.com/documento/dc_ba2a998d3326

How to cite

Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction? — Europe PMC PMID:42196179 — Europe PMC (en), https://europepmc.org/article/MED/42196179 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ba2a998d3326 (Metraipolis archive dc_ba2a998d3326, sha256 2a2834448e9e7e1a3a99a4b02ec05cff0e2487c11267106e83415f9652e69960)
BibTeX
@misc{dcba2a998d3326,
  title = {Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction? — Europe PMC PMID:42196179},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42196179},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ba2a998d3326; sha256 2a2834448e9e7e1a3a99a4b02ec05cff0e2487c11267106e83415f9652e69960},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42196179. Agents can read the archived copy with the MCP tool read_document.